Likewise, a large randomized, double-blind trial of intravenous magnesium in the post-MI period demonstrated no It remains quite rea- sonable to monitor potassium and magnesium during aggressive diuresis and in the post-MI period. 5.1.5.2. n-3 Fatty Acids and Lipids Both n-3 poly-unsaturated fatty acids and statin therapies may have a role in the prevention of SCD, thought to be due to a stabilization of the bilipid myo- cyte membrane involved in maintaining electrolyte Early data were promising regarding the effects of n-3 polyunsaturated fatty acids on the reduction of cardiovascular events and SCD. In 2006, a large meta- analysis of 19 observational and RCTs demonstrated a significant association between the consumption of n-3 polyunsaturated fatty acids and prevention of The randomized GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto)-Prevenzione trial in people with recent MI, found that fish oil 1 g/d reduced mortality, due to fewer SCD.S5.1.5.2-51 However, subsequent RCTs have not replicated these benefits and have shown n-3 polyunsaturated fatty acids to be Because studies showed a consistent lack of harm from n-3 polyunsaturated fatty acids, patients can be reassured of their safety. Longer- term data will hopefully clarify the conflicting results. In contrast, statin medications clearly reduce mor- tality and appear to reduce the risk of SCD related to ischemic heart disease.S5.1.5.2-57 The predominant mecha- nism remains uncertain. Prevention of coronary plaque rupture or a direct cardioprotective effect reducing VA has been suggested. 